Stocks › ROIV

Roivant Sciences Ltd.

ROIV·Nasdaq·USD
$38.66
-0.30 (-0.78%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ROIV
Roivant Sciences Ltd. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ROIVS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ROIV by members of U.S. Congress · 4 on record · 3 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Lisa C. McClainLisa C. McClainHouse · R · MI ROIVRoivant Sciences Ltd. · Stock Sale
$1,001 - $15,000
Nov 21, 2025 Oct 30, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI ROIVRoivant Sciences Ltd. · Stock Purchase
$1,001 - $15,000
Nov 21, 2025 Oct 30, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI ROIVRoivant Sciences Ltd. · Stock Sale
$1,001 - $15,000
Nov 21, 2025 Oct 31, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI ROIVRoivant Sciences Ltd. · Stock Purchase
$1,001 - $15,000
Aug 13, 2025 Jun 17, 2025 Filing ↗

Whale Activity

Position changes in ROIV reported for 2026-09-30 by 590 institutional filers
Increased: 224New: 98Held: 51Decreased: 128Closed: 67No prior filing: 22
  • Increased224
  • New98
  • Held51
  • Decreased128
  • Closed67
  • No prior filing22
FilerSharesValueChange
FMR LLC85.6M$3.13Bincreased
BlackRock, Inc.61.9M$2.26Bincreased
MORGAN STANLEY38.6M$1.41Bdecreased
QVT Financial LP23.7M$867.6Mheld
VANGUARD CAPITAL MANAGEMENT LLC23.1M$845.8Mincreased
STATE STREET CORP22.4M$819.2Mincreased
FARALLON CAPITAL MANAGEMENT, L.L.C.21.7M$795.2Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC21.7M$792.0Mincreased
UBS Group AG13.9M$509.4Mdecreased
GEODE CAPITAL MANAGEMENT, LLC12.5M$468.0Mincreased
JENNISON ASSOCIATES LLC12.1M$441.3Mincreased
ADAGE CAPITAL PARTNERS GP, L.L.C.11.0M$402.3Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ROIV insiders, by quarter · Form 4
-20.0M-10.0M010.0M20.0M2025 Q1: -1.6M2025 Q12025 Q2: -4.1M2025 Q22025 Q3: -3.7M2025 Q32025 Q4: -13.8M2025 Q42026 Q1: -5.3M2026 Q12026 Q2: -3.6M2026 Q22026 Q3: -1.6M2026 Q32026 Q4: -2.5M2026 Q4

Recent Insider Transactions

834 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
MANCHESTER KEITH SDirector · Director Sale −798 $38.24 $31K Nov 17, 2026 Form 4 ↗
MANCHESTER KEITH SDirector · Director Sale −75.7K $38.24 $2.9M Nov 17, 2026 Form 4 ↗
MANCHESTER KEITH SDirector · Director Sale −525.5K $38.24 $20.1M Nov 17, 2026 Form 4 ↗
MANCHESTER KEITH SDirector · Director Sale −79.5K $39.17 $3.1M Nov 16, 2026 Form 4 ↗
MANCHESTER KEITH SDirector · Director Sale −550.3K $39.17 $21.6M Nov 16, 2026 Form 4 ↗
MANCHESTER KEITH SDirector · Director Sale −18.9K $38.99 $738K Nov 16, 2026 Form 4 ↗
MANCHESTER KEITH SDirector · Director Sale −131.1K $38.99 $5.1M Nov 16, 2026 Form 4 ↗
Pulik RichardCFO Sale −82.2K $42.03 $3.5M Nov 11, 2026 Form 4 ↗
Pulik RichardCFO Sale −47.6K $41.89 $2.0M Nov 11, 2026 Form 4 ↗
Pulik RichardCFO Sale −45.2K $41.47 $1.9M Nov 11, 2026 Form 4 ↗
Pulik RichardCFO Sale −125.0K $41.20 $5.2M Nov 10, 2026 Form 4 ↗
Venker EricPresident & Immunovant CEO Sale −29.7K $41.00 $1.2M Nov 10, 2026 Form 4 ↗
Venker EricPresident & Immunovant CEO Sale −158.2K $40.44 $6.4M Nov 10, 2026 Form 4 ↗
Venker EricPresident & Immunovant CEO Sale −200.0K $36.31 $7.3M Nov 3, 2026 Form 4 ↗
Venker EricPresident & Immunovant CEO Sale −200.0K $36.59 $7.3M Oct 28, 2026 Form 4 ↗
Venker EricPresident & Immunovant CEO Sale −185.9K $35.09 $6.5M Oct 20, 2026 Form 4 ↗
Venker EricPresident & Immunovant CEO Sale −14.1K $35.42 $501K Oct 20, 2026 Form 4 ↗
Epperly Melissa B,Director · Director Sale −900 $36.57 $33K Oct 1, 2026 Form 4 ↗
Epperly Melissa B,Director · Director Sale −16.9K $36.08 $608K Oct 1, 2026 Form 4 ↗
Venker EricPresident & Immunovant CEO Sale −200.0K $36.62 $7.3M Sep 30, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ROIV · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
16.0M$565.8M0.02%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
11.5M$408.6M0.22%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
6.7M$235.6M0.50%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
5.2M$182.9M0.19%Jun 30, 2026
Invesco S&P MidCap Momentum ETF
Invesco Exchange-Traded Fund Trust
5.2M$177.0M2.47%Jul 31, 2026
VANGUARD EXPLORER FUND3.0M$100.7M0.46%Jul 31, 2026
VANGUARD HEALTH CARE INDEX FUND
VANGUARD WORLD FUND
1.4M$49.2M0.22%Aug 31, 2026
Dimensional U.S. Core Equity 2 ETF
Dimensional ETF Trust
1.2M$39.5M0.08%Jul 31, 2026
iShares Russell 1000 Value ETF
iShares Trust
1.1M$38.7M0.05%Jun 30, 2026
VANGUARD S&P MID-CAP 400 INDEX FUND
VANGUARD ADMIRAL FUNDS
741.7K$25.7M0.44%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list ROIV's shares (CUSIP G76279101), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 85.6M shares11.8%
    Nov 5, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 85.6M shares11.8%
    Nov 5, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 59.3M shares8.2%
    Oct 27, 2026 · ↗
  • Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 39.4M shares5.5%
    Aug 13, 2026 · ↗
  • Morgan StanleySCHEDULE 13G/A · passive (13G) · 40.7M shares5.7%
    Aug 13, 2026 · ↗
  • Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 48.3M shares6.7%
    May 12, 2026 · ↗
  • Morgan StanleySCHEDULE 13G/A · passive (13G) · 49.5M shares6.9%
    May 12, 2026 · ↗
  • Ramaswamy VivekSCHEDULE 13G/A · passive (13G) · 25.5M shares3.6%
    May 6, 2026 · ↗
  • Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 54.4M shares7.8%
    Feb 11, 2026 · ↗
  • Morgan StanleySCHEDULE 13G/A · passive (13G) · 55.5M shares8.0%
    Feb 11, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming roivant sciences as client

No lobbying filings found naming Roivant Sciences Ltd. as the client.

  • THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2022 Q1—
    Filing ↗
  • THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q4 · BUD, MED$20K
    Filing ↗
  • THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q3 · BUD, MED$20K
    Filing ↗
  • BAKER DONELSON BEARMAN CALDWELL & BERKOWITZROIVANT SCIENCES, INC. · 2021 Q2—
    Filing ↗
  • THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q2 · MED, BUD$20K
    Filing ↗

Government Contracts

Federal awards to Roivant Sciences Ltd. · USAspending

No federal contract awards found for Roivant Sciences Ltd..

U.S. Patents

Recent USPTO applications naming Roivant Sciences Ltd.

No USPTO patent applications found for Roivant Sciences Ltd..

Annual Financials

From ROIV's 10-K filings · XBRL
Fiscal yearFY2026FY2025FY2024FY2023FY2022
Revenue$8.3M$29.1M$32.7M$31.5M$55.3M
Operating income-$515.1M-$1.00B$4.50B-$906.8M-$1.35B
Net income-$299.8M-$172.0M$4.35B-$1.01B-$845.3M
Diluted EPS-$0.54-$0.24$5.23-$1.42-$1.26
Operating cash flow-$750.3M-$839.5M-$765.3M-$843.4M-$677.7M
Cash and equivalents$1.42B$2.72B$6.49B$1.68B$2.06B
Total assets$5.71B$5.44B$7.22B$2.39B$2.59B
Total liabilities$416.3M$249.7M$774.0M$782.0M$523.7M
Shareholders' equity$4.53B$4.69B$5.97B$1.16B$1.66B

As Roivant Sciences Ltd. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed May 20, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in ROIV's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureOct 21, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 9.01Shareholder voteSep 18, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureSep 8, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 28, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureAug 27, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 20, 2026
    EDGAR ↗

About Roivant Sciences Ltd.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersLONDON
IncorporatedD0